IE45441L - Influenza virus vaccine. - Google Patents

Influenza virus vaccine.

Info

Publication number
IE45441L
IE45441L IE771237A IE123777A IE45441L IE 45441 L IE45441 L IE 45441L IE 771237 A IE771237 A IE 771237A IE 123777 A IE123777 A IE 123777A IE 45441 L IE45441 L IE 45441L
Authority
IE
Ireland
Prior art keywords
influenza
strain
influenza virus
type
virus
Prior art date
Application number
IE771237A
Other versions
IE45441B1 (en
Original Assignee
Rit Rech Ind Therapeut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rit Rech Ind Therapeut filed Critical Rit Rech Ind Therapeut
Publication of IE45441L publication Critical patent/IE45441L/en
Publication of IE45441B1 publication Critical patent/IE45441B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Attenuated vaccine against influenza contains as active ingredient a strain of attenuated H3N2 type influenza virus resistant to serum inhibitors. The strain is influenza virus strain P/76/7. Used as vaccine against influenza suitable for intranasal administration. Pref. a unit dose of the vaccine contains at least 107 DIO50 (infective dose of 50% of inoculated eggs) of the P/76/7 virus strain. The parent patent BE 819865 describes a method of obtaining stable strains of influenza virus type A (H3N2) which are resistant to serum inhibitors. Each year the serotype of influenza virus type A in the world differs slightly from the strains observed the previous year; this antigenic modification causing problems for immunisation against influenza type A. To obtain maximum effect the vaccinal antigen must be nearest to the dominant virus and thus influenza vaccines are periodically adapted to give maximum protection against these new strains, the present addition comprising such a modification. [DE2726837A1]
IE1237/77A 1976-06-18 1977-06-16 Live influenza virus vaccine and preparation thereof IE45441B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE843094 1976-06-18

Publications (2)

Publication Number Publication Date
IE45441L true IE45441L (en) 1977-12-18
IE45441B1 IE45441B1 (en) 1982-08-25

Family

ID=3861379

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1237/77A IE45441B1 (en) 1976-06-18 1977-06-16 Live influenza virus vaccine and preparation thereof

Country Status (6)

Country Link
JP (1) JPS52156920A (en)
AT (1) AT351160B (en)
DE (1) DE2726837A1 (en)
IE (1) IE45441B1 (en)
LU (1) LU77552A1 (en)
ZA (1) ZA773594B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration

Also Published As

Publication number Publication date
ATA423877A (en) 1978-12-15
AT351160B (en) 1979-07-10
ZA773594B (en) 1978-05-30
IE45441B1 (en) 1982-08-25
LU77552A1 (en) 1977-09-19
JPS52156920A (en) 1977-12-27
DE2726837A1 (en) 1977-12-29

Similar Documents

Publication Publication Date Title
Webster et al. Cross‐protection and cross‐reactive cytotoxic T cells induced by influenza virus vaccines in mice
Jones et al. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms)
Schulman et al. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus
Johansson et al. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice
Glathe et al. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people
Tamura et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine
KR950701822A (en) Combined vaccines comprising hepatitis B surface antigen and other antines
FI905184A0 (en) CHIMERIC GLYCOPROTEINER SOM INNEHAOLLER IMMUNOGENIC DELAR AV HUMAN PARAINFLUENSA VIRUS TYPE 3.
Byars et al. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation
Scott et al. Responses of mice immunized with influenza virus by serosol and parenteral routes
Barry et al. Inactivated influenza vaccine efficacy: diminished antigenicity of split-product vaccines in mice
Jones et al. A nasal Proteosome™ influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity
Ben Ahmeida et al. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus
JP2000512263A (en) Flu vaccine
Le Cam et al. Adjuvants for influenza vaccine
Laver et al. Diversity of the antibody response to the different antigenic determinants on the hemagglutinin subunits of influenza viruses
IE45441L (en) Influenza virus vaccine.
JPS58407B2 (en) Method for separating hemagglutinin and neuraminidase components from influenza virus
DE2966914D1 (en) Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses, process for preparing it, adeno-like and newcastle disease virus strains
Jemski et al. Aerosol vaccination of mice with a live, temperature-sensitive recombinant influenza virus
Liashenko et al. Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16
Fenters et al. Enhanced immunogenicity in mice of a purified, tween-ether-treated influenza vaccine
McLaren et al. Immunity to influenza in ferrets: XII. Immunization of ferrets with TNBP-split influenza virus vaccine
McLaren et al. Immunity to influenza in ferrets: XI. Cross-immunity between A/Hong Kong/68 and A/England/72 viruses: serum antibodies produced by infection or immunization
ES486441A0 (en) METHOD FOR PREPARING A VACCINE CONTAINING VIRUS DISABLED FROM FELINE INFECTIOUS PERITONILIS.